Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Florence, Alabama, United States
Pfizer Investigational Site
Muscle Shoals, Alabama, United States
Pfizer Investigational Site
Scottsdale, Arizona, United States
Pfizer Investigational Site
Hot Springs, Arkansas, United States
Pfizer Investigational Site
Antioch, California, United States
Pfizer Investigational Site
Burbank, California, United States
Pfizer Investigational Site
Downey, California, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Start Date
July 1, 2007
Primary Completion Date
July 1, 2010
Completion Date
December 1, 2012
Last Updated
October 29, 2013
960
ACTUAL participants
erlotinib
DRUG
sunitinib
DRUG
erlotinib
DRUG
placebo
DRUG
Lead Sponsor
Pfizer
NCT06549816
NCT04151563
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06127329